Dossier assessment
Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with advanced renal cell carcinoma following one prior VEGF-targeted therapy
Added benefit not proven
Project details
- Project no.
- A20-122
- Commission
- Commission awarded on 17.12.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed